Difference between revisions of "Napsin A"
Jump to navigation
Jump to search
Jensflorian (talk | contribs) (+ images) |
|||
Line 14: | Line 14: | ||
*[[Pancreatic adenocarcinoma]].<ref name=pmid19740516/> | *[[Pancreatic adenocarcinoma]].<ref name=pmid19740516/> | ||
*[[Breast carcinoma]] (0 positive of 17 cases<ref name=pmid19740516/>). | *[[Breast carcinoma]] (0 positive of 17 cases<ref name=pmid19740516/>). | ||
<gallery> | |||
File:Adenocarcinoma - Napsin A immunostain (6838767882).jpg | Napsin in pulomonary adenocarcinoma (WC/Yale Rosen) | |||
File:Adenocarcinoma - Napsin A immunostain (5762462036).jpg | Coarse Napsin staining pattern (WC/Yale Rosen) | |||
</gallery> | |||
==See also== | ==See also== |
Revision as of 13:28, 8 October 2015
Napsin A, also Napsin, is a commonly used immunostain in pulmonary pathology.
Positive
- Lung adenocarcinoma - 83% of cases.[1]
- Papillary renal cell carcinoma 79% of cases.[1]
Occasionally positive
- Clear cell renal cell carcinoma - 34% of cases.[1]
- Papillary thyroid carcinoma - 2/81 cases, tall cell variant only.[1]
Negative
- Squamous cell carcinoma of the lung.[1]
- Colorectal adenocarcinoma.[1]
- Pancreatic adenocarcinoma.[1]
- Breast carcinoma (0 positive of 17 cases[1]).
See also
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Bishop, JA.; Sharma, R.; Illei, PB. (Jan 2010). "Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma.". Hum Pathol 41 (1): 20-5. doi:10.1016/j.humpath.2009.06.014. PMID 19740516.